Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-04-12-Speech-2-073"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20050412.8.2-073"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, I welcome this Commission Statement on malaria, because three years ago, by approving our contribution to the budget of the Global Fund to Fight Malaria, Tuberculosis and AIDS, the Commission accepted Parliament’s request that it report to us regularly, and the previous Commission did not always do so. Furthermore, because in the fight against contagious diseases linked to poverty, AIDS is often the focus of attention, despite the fact that tuberculosis and malaria claim more victims every year and there is more chance of their being eradicated.
Just a few years ago, malaria seemed close to eradication in many countries; today it is the most frequent cause of death in sub-Saharan Africa, affecting more people and regions in which it had been eradicated. Recent figures suggest that there are more than 3 million direct and indirect victims of malaria each year. It is good that the Commission should promote the debate on the national protocols on the treatment of malaria, but that is not the most important thing if the objective is to include new therapeutic combinations, such as artemisinin and other therapeutic drugs. Mosquito nets treated with insecticides and intermittent preventive treatments significantly reduce morbimortality, but so far only Vietnam and certain countries in Latin America are showing encouraging results. In Africa, less than 10% of exposed children sleep protected by mosquito nets and the systematic use of those nets only protects 1% of the population at risk.
The Commission, as a member of the governing council of the United Nations Fund for fighting these diseases, should increase the attention paid to malaria and, in view of experience, it should do the same with the sixth and seventh framework programmes for research and technological development, to which we provide EUR 400 million for research into these diseases, and thereby assist greater numbers of people at less economic cost, although that means fewer profits for the pharmaceutical industry."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples